Recent Articles from TheStreet

DraftKings Lead

DraftKings Stock Lower After $22 Billion Entain Takeover Deadline Extension

DraftKings will now have until November 16 to formalize its $22.4 billion bid for Entain, or walk away from the British bookmaker for at least six months.

Applied Materials Lead

Applied Materials Stock Up; JPMorgan Likes Chip-Capital-Spending Outlook

Applied Materials should benefit as 'semiconductor capital spending environment remains constructive,' JPMorgan says.

Bitcoin Lead

Cryptocurrency Price Check: Bitcoin Climbs, Invesco Bails on Futures Product

Bitcoin rises as the ProShares Bitcoin Strategy ETF is set to begin trading on the NYSE.

Walmart Family-Run Business Lead

Walmart Joins Goldman Sachs Conviction List; Target Removed

Goldman Sachs 'remains constructive on fundamentals' for both Walmart and Target 'into 2022,' wrote analyst Kate McShane.

What Is Coinbase and How Do You Use It?

Coinbase Stock Jumps After Pilot Deal With Facebook Digital Wallet Novi

Coinbase will store Pax dollar funds from a pilot project of Facebook's Novi digital wallet in its $180 billion custody division.

Kansas City Southern Railway Lead

Kansas City Southern Stock Slips on Third-Quarter Earnings Miss

Kansas City Southern shares slip after the company misses Wall Street's third-quarter earnings forecasts.

Quitting Jobs Lead

Manpower Shares Drop as Revenue Trails Analyst Forecasts

Manpower's revenue jumped 12% to $5.14 billion but lagged the FactSet analyst consensus of $5.3 billion.

Halliburton Fuels 14% Profit Jump With Higher North American Demand

Halliburton Stock Falls as Revenue Misses, Earnings in Line

Halliburton shares were lower after the oil-services giant reported bottom-line results that matched estimates while missing on revenue.

What to Watch Tuesday: Procter & Gamble Earnings, Inflation Data

Premarket Movers Tuesday - Procter & Gamble, Ulta, Netflix

Stocks moving in premarket trading include Procter & Gamble. Ulta, Netflix, Johnson & Johnson and Teladoc.

After Red-hot IPO, Chinese Biotech Firm Kintor Eyes Blockbuster Drugs For Prostate Cancer, Sex Hormone-related Hair Loss

Atea Pharma Stock Plunges After COVID Treatment Trial Disappoints; Merck Jumps

Atea Pharmaceuticals could shed more than $2 billion in value Tuesday after the drugmaker said a mid-stage trial of its developing COVID treatment failed to meet expectations.